engleski

Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data

Purpose: To assess the potential effectiveness of a co-designed reduced visit pathway of care for individuals living with stable HIV in terms of empowerment (which encapsulates patient confidence, skills and knowledge to self-manage health and care). Methods: People living with stable HIV across five diverse clinical sites in Europe were invited to take part in the EmERGE study - whereby individuals are seen once, instead of twice, a year by their clinician - with their interim visit supported via an mHealth platform. We report here on preliminary data on the primary outcome, empowerment, measured by PAM-13 (Patient Activation Measure-13) at baseline (M0) and 12 months (M12). Results: PAM-13 was available on 2112/2251 (93.8%) of participants at M0 and 1026/1439 (72.3%) at M12. The overall proportion of participants at low activation Levels (L) 1&2 was 12.4% (261/2112) at baseline, ranging from 10.5% in Antwerp to 13.5% in Zagreb. At M12, the overall proportion was 14.1% (145/1026), ranging from 9.0% in Zagreb to 17.1% in Barcelona. Change in activation from L1&2 at baseline to L3&4 at M12 was achieved by 63/101 (62.4%) L1&2 baseline participants whilst 93/891 (10.4%) of baseline participants at L3&4 had dropped to L1&2 by M12 ; 836/992 (84.3%) did not switch between L1&2 and L3&4. The distribution of participants across each of the four levels of PAM-13 was similar across sites at baseline with≥86% of participants with the highest levels of activation. At four out of five sites, the proportion at L3&4 is currently lower at M12 than at M0. Conclusions: The majority of participants had a high level of empowerment at baseline. Over 60% of respondents in the lowest categories of PAM-13 (L1&2) at baseline shifted to L3&4 in M12. The proportion of participants at low activation levels was similar between sites. Follow-up continues until October 2019.

EmERGE mHealth platform ; Users

nije evidentirano